May 3, 2022 – The pressures were immediate, and daunting. Early in the pandemic, Quidel, a leading manufacturer of diagnostic solutions, was being asked to go from manufacturing 50 to 60 million tests per year, to producing 16 million a week.
“That does not happen overnight,” said Quidel President and CEO Doug Bryant. Fortunately, the company was up to the task, and in the span of two plus years has transformed its capabilities in servicing the U.S. healthcare industry during a crisis.
In a wide-ranging conversation with Repertoire Publisher Scott Adams, Bryant discussed Quidel’s mobilization amid the pandemic, how its relationships with distribution partners have helped in the past couple of years, and how the organization’s unique culture has contributed to its transformation in a severely disrupted marketplace.Read the story in the latest issue of Repertoire